Literature DB >> 14985276

Cutaneous injection site reactions to long-term therapy with enfuvirtide.

Paolo Maggi1, Nicoletta Ladisa, Eliana Cinori, Andrea Altobella, Giuseppe Pastore, Raffaele Filotico.   

Abstract

OBJECTIVE: Enfuvirtide is the first of a new class of antiretroviral agents. The drug is safe and well tolerated; injection site reactions are the most common adverse events. The aim of this study was the clinical and histopathological evaluation of injection site reactions in patients treated for 80 weeks.
MATERIALS AND METHODS: Six patients were evaluated. Five of them underwent cutaneous biopsies using a 4 mm punch. Sections were stained with haematoxylin-eosin, periodic acid-Schiff stain and Verhoeff's stain. Moreover, immunohistochemical studies were carried out using CD20, CD45Ro and CD34 antibodies.
RESULTS: Four different macroscopic patterns were presented: (a) no evidence of cutaneous lesions; (b) transient infiltrative lesions which auto-resolved within 24 h; (c) transient nodular lesions which auto-resolved within 7-15 days; and (d) stable lesions after more than 30 days with a scleroderma-like aspect. Histological examination showed three patterns: (1) an acute urticaria/vasculitis-like pattern with inflammation of the fat tissue; (2) a sub-acute pattern with an initial dermal sclerosis; (3) a chronic scleroderma-like pattern with connective tissue disposed around the adnexa, whose structure was intact. The immunohistochemical study evidenced a prevalence of T lymphocytes and a moderate neoangiogenesis.
CONCLUSIONS: In our experience, after a rather long period of treatment, cutaneous reactions comprised a variety of features largely independent of the virological and immunological outcome. The adnexa was unaltered in all patients, this indicating a tendency to a possible regression of the sclerotic lesions. Therefore, patients should be encouraged to rotate the sites of injection thus permitting the tissues to regenerate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985276     DOI: 10.1093/jac/dkh141

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?

Authors:  Paolo Maggi; Raffaele Filotico; Stefano Bonora; Anna Volpe; Chiara Bellacosa; Eliana Cinori; Daniel Gonzalez de Requena; Antonio D'Avolio; Giovanni Di Perri
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

2.  Antiretroviral nanoparticles: the future is now: authors' response to editorial comments.

Authors:  Jennifer P Freeling; Rodney J Y Ho
Journal:  AIDS       Date:  2015-04-24       Impact factor: 4.177

Review 3.  HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2007-03-01       Impact factor: 2.332

4.  Peptide-Based HIV Entry Inhibitors.

Authors:  Jing Pu; Qian Wang; Shibo Jiang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.

Authors:  Thierry Huet; Olivier Kerbarh; Dominique Schols; Pascal Clayette; Cécile Gauchet; Guy Dubreucq; Loïc Vincent; Heidi Bompais; Romain Mazinghien; Olivier Querolle; Arnaud Salvador; Jérôme Lemoine; Bruno Lucidi; Jan Balzarini; Maurice Petitou
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

6.  Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.

Authors:  Cheryl A Stoddart; Geneviève Nault; Sofiya A Galkina; Karen Thibaudeau; Peter Bakis; Nathalie Bousquet-Gagnon; Martin Robitaille; Maryanne Bellomo; Véronique Paradis; Patricia Liscourt; Alexandra Lobach; Marie-Eve Rivard; Roger G Ptak; Marie K Mankowski; Dominique Bridon; Omar Quraishi
Journal:  J Biol Chem       Date:  2008-09-22       Impact factor: 5.157

Review 7.  Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.

Authors:  Jing Pu; Qian Wang; Wei Xu; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2019-08-01       Impact factor: 5.048

8.  Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.

Authors:  Xiaojie Zhu; Yun Zhu; Sheng Ye; Qian Wang; Wei Xu; Shan Su; Zhiwu Sun; Fei Yu; Qi Liu; Chao Wang; Tianhong Zhang; Zhenqing Zhang; Xiaoyan Zhang; Jianqing Xu; Lanying Du; Keliang Liu; Lu Lu; Rongguang Zhang; Shibo Jiang
Journal:  Sci Rep       Date:  2015-08-19       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.